Clinical factors associated with initiation of and persistence with ADP receptor-inhibiting oral antiplatelet treatment after acute coronary syndrome: a nationwide cohort …
T Prami, H Khanfir, A Deleskog, P Hasvold, V Kytö… - BMJ open, 2016 - bmjopen.bmj.com
Objectives To study patient selection for and persistence with ADP receptor-inhibiting oral
antiplatelet (OAP) treatment after acute coronary syndrome (ACS). Design Observational …
antiplatelet (OAP) treatment after acute coronary syndrome (ACS). Design Observational …
Real world insights on the initiation and treatment duration of oral antiplatelets in acute coronary syndromes: a retrospective cohort study
MJ Claeys, C Beauloye, S Pourbaix… - European Heart …, 2017 - academic.oup.com
Aims This study is a real world, observational study evaluating the treatment persistence of
oral antiplatelet (OAP) therapy during a one-year follow-up in patients after an acute …
oral antiplatelet (OAP) therapy during a one-year follow-up in patients after an acute …
Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes
JP Collet, G Montalescot, B Blanchet, ML Tanguy… - Circulation, 2004 - Am Heart Assoc
Background—Oral antiplatelet agents (OAAs) can prevent further vascular events in
cardiovascular disease. How prior use or recent discontinuation of OAA affects clinical …
cardiovascular disease. How prior use or recent discontinuation of OAA affects clinical …
Adherence to guidelines and registry data
S Agewall - European Heart Journal–Cardiovascular …, 2017 - academic.oup.com
In this issue of the journal, Dr Claeys and co-workers from Belgium report real-world data in
a multicentre study, evaluating the treatment persistence of oral antiplatelet (OAP) therapy …
a multicentre study, evaluating the treatment persistence of oral antiplatelet (OAP) therapy …
Early cessation of adenosine diphosphate receptor inhibitors among acute myocardial infarction patients treated with percutaneous coronary intervention: insights …
EL Fosbøl, C Ju, KJ Anstrom, ME Zettler… - Circulation …, 2016 - Am Heart Assoc
Background—Guidelines recommend the use of adenosine diphosphate receptor inhibitor
(ADPri) therapy for 1 year postacute myocardial infarction; yet, early cessation of therapy …
(ADPri) therapy for 1 year postacute myocardial infarction; yet, early cessation of therapy …
Initiation and persistence with antiplatelet agents among the patients with acute coronary syndromes: a retrospective, observational database study in China
X Liu, X He, J Wu, D Luo - Patient preference and adherence, 2019 - Taylor & Francis
Objectives To investigate the initiation and persistence of antiplatelet agents and the
associated factors for patients with acute coronary syndromes (ACS) in Tianjin, China …
associated factors for patients with acute coronary syndromes (ACS) in Tianjin, China …
Longitudinal treatment patterns with ADP receptor inhibitors after myocardial infarction: Insights from the Canadian Observational AntiPlatelet sTudy
A Bagai, TY Wang, SG Goodman, HN Fisher… - International Journal of …, 2017 - Elsevier
Background After myocardial infarction (MI) treated with percutaneous coronary intervention
(PCI), guidelines recommend dual antiplatelet therapy (DAPT) with aspirin and an ADP …
(PCI), guidelines recommend dual antiplatelet therapy (DAPT) with aspirin and an ADP …
In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention …
A Bagai, ED Peterson, E Honeycutt… - … Heart Journal: Acute …, 2015 - academic.oup.com
Aims While randomized clinical trials have compared clopidogrel with higher potency
adenosine diphosphate (ADP) receptor inhibitors among patients with acute myocardial …
adenosine diphosphate (ADP) receptor inhibitors among patients with acute myocardial …
Increased uptake of guideline-recommended oral antiplatelet therapy: insights from the Canadian acute coronary syndrome reflective
S Gandhi, B Zile, MK Tan, J Saranu, C Bucci… - Canadian Journal of …, 2014 - Elsevier
Current guideline-based recommendations for oral dual-antiplatelet therapy in an acute
coronary syndrome (ACS) include the use of newer adenosine diphosphate receptor …
coronary syndrome (ACS) include the use of newer adenosine diphosphate receptor …
Patterns of treatment with antiplatelet therapy after an acute coronary syndrome: data from a large database in a community setting
C Cimminiello, L Dondi, A Pedrini… - European Journal of …, 2019 - academic.oup.com
Aims Current guidelines strongly recommend antiplatelet therapy with aspirin plus a P2Y12
receptor inhibitor (dual therapy) for patients with acute coronary syndrome (ACS). To better …
receptor inhibitor (dual therapy) for patients with acute coronary syndrome (ACS). To better …